Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 known ✓ | P0DMS8 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 7/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.54 |
| ▸ | MAPT | P10636 | 4/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.54 |
| ▸ | TP53 | P04637 | 3/20 | 0.54 |
| ▸ | USP2 | O75604 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | HBB | P68871 | 1/20 | 0.54 |
| ▸ | ABCB1 | P08183 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | APP | P05067 | 3/20 | 0.45 |
| ▸ | FLT3 | P36888 | 3/20 | 0.43 |
| ▸ | MMP3 | P08254 | 1/20 | 0.43 |
| ▸ | MMP9 | P14780 | 1/20 | 0.43 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20535339 | 0.87 | MAPT (0.67) | MEN1KMT2AMAPTKDM4ETP53 | |
| SCHEMBL28365603 | 0.84 | MAPT (0.64) | MEN1KMT2AMAPTKDM4ETP53 | |
| SCHEMBL22459378 | 0.78 | MAPT (0.65) | MEN1KMT2AMAPTKDM4ETP53 | |
| SCHEMBL20534813 | 0.77 | MAPT (0.64) | MEN1KMT2AMAPTKDM4ETP53 | |
| SCHEMBL27350540 | 0.77 | ABCB1 (0.71) | MEN1KMT2AMAPTKDM4ETP53 | |
| SCHEMBL22459586 | 0.77 | ABCB1 (0.53) | MEN1KMT2AMAPTKDM4ETP53 | |
| SCHEMBL22812901 | 0.76 | MEN1 (0.64) | MEN1KMT2AMAPTKDM4ETP53 | |
| SCHEMBL22459984 | 0.75 | MAPT (0.61) | MEN1KMT2AMAPTKDM4ETP53 | |
| SCHEMBL22459584 | 0.75 | MAPT (0.77) | MEN1KMT2AMAPTKDM4ETP53 | |
| SCHEMBL22460005 | 0.74 | MEN1 (0.70) | MEN1KMT2AMAPTKDM4ETP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11110105-B2 | Compounds, composition and uses thereof for treating cancer | INSTITUT GUSTAVE ROUSSY (FR) | 2021-09-07 | — | — | US | disclosed |
| EP-3609878-B1 | COMPOUNDS, COMPOSITION AND USES THEREOF FOR TREATING CANCER | ROUSSY INST GUSTAVE (FR) | 2020-12-23 | — | — | EP | disclosed |
| US-20200297741-A1 | COMPOUNDS, COMPOSITION AND USES THEREOF FOR TREATING CANCER | Institut National de la Santé et de la Recherche Médicale (FR) | 2020-09-24 | — | — | US | disclosed |
| EP-3609878-A1 | COMPOUNDS, COMPOSITION AND USES THEREOF FOR TREATING CANCER | Institut Gustave Roussy (FR) | 2020-02-19 | — | — | EP | disclosed |
| WO-2018189210-A1 | COMPOUNDS, COMPOSITION AND USES THEREOF FOR TREATING CANCER | INSTITUT GUSTAVE ROUSSY (FR) | 2018-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200297741-A1 | COMPOUNDS, COMPOSITION AND USES THEREOF FOR TREATING CANCER | PTPRC, PTPRS, PTPRCAP | ADORA3 1288/4885MEN1 2190/4885KMT2A 3703/4885 |
| US-11110105-B2 | Compounds, composition and uses thereof for treating cancer | PTPRC, PTPRS, PTPRCAP | ADORA3 1288/4885MEN1 2190/4885KMT2A 3703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.